Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals is a clinical-stage biotechnology company focused on developing localized delivery, extended-release alternatives to currently approved drugs. Each of Eupraxia Pharmaceuticals' product candidates has the potential to address therapeutic areas with significant unmet medical needs, and the company strives to enhance patient benefits by providing targeted, long-lasting activity with fewer side effects. The company’s lead product candidate, EP-104IAR, is currently in Phase II development for the treatment of pain associated with knee osteoarthritis. With the launch of a program targeting eosinophilic esophagitis (EoE), the EP-104 platform has expanded into gastrointestinal diseases. Eupraxia Pharmaceuticals is also developing late-stage and early-stage long-acting formulations. Potential pipeline indications include other inflammatory joint conditions and oncology candidates, each designed to improve the efficacy and tolerability of currently approved drugs.